SHAREHOLDER ALERT: WeissLaw LL – GuruFocus.com
NEW YORK, November 18, 2021
NEW YORK, November 18, 2021 / PRNewswire / – WeissLaw LLP investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Dicerna Pharmaceuticals, Inc. (“Dicerna” or the “Company”) (NASDAQ: DRNA) in connection with the proposed acquisition of the Company by Novo Nordisk. Under the terms of the Merger Agreement, the shareholders of the Company will receive $ 38.25 per share in cash for each Dicerna common share they hold. The all-cash transaction is valued at $ 3.3 billion.
If you own Dicernashares and would like to discuss this survey or if you have any questions regarding this notice or your rights or interests, visit our website:
Or please contact:
Joshua Rubin, Esq.
305 Broadway, 7e Ground
New York, New York State 10007
WeissLaw LLP is considering whether (i) the board of directors of Dicerna acted in the best interests of the shareholders of Dicerna in accepting the proposed transaction, (ii) the consideration for the merger per share adequately remunerates the shareholders of Dicerna, and (iii ) whether all information regarding the process undertaken by the board of directors and the evaluation of the transaction will be fully and fairly disclosed.
WeissLaw LLP has litigated hundreds of class and derivative shareholder actions for breach of corporate and fiduciary obligations. We have recovered over $ 1 billion for defrauded clients and obtained significant corporate governance relief in many of these cases. If you have information or want legal advice regarding possible corporate wrongdoing (including insider trading, waste of company assets, accounting fraud or misleading information), fraud consumers (including false advertising, defective products, or other deceptive marketing practices), or violations of antitrust laws, please email us at [emailÂ protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-dicerna-pharmaceuticals-inc-301428736.html
SOURCE WeissLaw LLP